Precision Medicine for Nutrition in EDEN
EDEN 的精准营养医学
基本信息
- 批准号:10644738
- 负责人:
- 金额:$ 11.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:Acute Lung InjuryAcute Respiratory Distress SyndromeAdvocateAffectBiologicalBiological AssayBiological MarkersBiological Specimen BanksCaringCategoriesClinicalComplexComputer ModelsCritical CareCritical IllnessDataDietary InterventionDiseaseEndocrineEnrollmentEnteralEnteral FeedingEnteral NutritionFeedsFundingFutureGastric Inhibitory PolypeptideGoalsGuidelinesHeterogeneityHormonesHyperglycemiaImmune responseIndividualInflammationInflammatoryInsulinIntakeIntestinal permeabilityIntestinesInvestigationIschemiaKnowledgeLaboratoriesLifeLiquid substanceMethodologyModelingMulticenter TrialsNational Heart, Lung, and Blood InstituteNausea and VomitingNutrientNutrition TherapyNutritional StudyObservational StudyOutcomeParticipantPathway interactionsPatientsPatternPermeabilityPersonsPhenotypePhysical FunctionPhysiologicalPopulationPrediction of Response to TherapyProcessPrognosisRandomizedRecommendationRecoveryRiskRouteSecondary toSeverity of illnessStomachTestingThinnessadverse outcomecell motilitydemographicsfrontiergastrointestinalglucagon-like peptide 1glucose metabolismgut inflammationimprovedincretin hormoneindividual patientinsulin secretionintestinal fatty acid binding proteinlung injurymortalitymuscle formnext generationnovelnutritionpersonalized careprecision medicineprecision nutritionpredictive markerpreventresponsesecondary analysisstandard of caresystemic inflammatory responsetreatment effecttreatment responseventilation
项目摘要
PROJECT ABSTRACT
Nutrition is an essential component in the care of critically ill patients with acute respiratory distress syndrome
(ARDS) who are often limited in volitional intake and who incur new deficits in physical function secondary to
their illness. Despite well-characterized associations between inadequate nutrition and adverse outcomes,
large multicenter trials of specific nutrition strategies have failed to consistently demonstrate clinical benefit
with any particular approach. The landmark NHLBI-funded Early versus Delayed Enteral Nutrition [EDEN] trial
investigated low-level (trophic) versus full enteral feeds in 1000 patients and demonstrated increased
gastrointestinal complications with full enteral feeds without any clinical benefit. Subsequently, current
guidelines recommend low-level feeds for all ARDS patients, however, ARDS is increasingly recognized as a
heterogeneous disease and a one-size-fits-all approach may not be appropriate. An essential first step in
individualizing nutrition in ARDS is identifying the clinical and biologic variables that contribute to heterogeneity
of treatment effect whereby individuals or groups vary in response to treatment. Thus, the overall goal of this
proposal is to characterize differential responses to nutrition by leveraging data and biospecimens from the
EDEN trial. In Aim 1, this proposal will investigate whether ARDS subphenotypes differed in response to low-
level versus full enteral nutrition in EDEN. Recent studies have identified two distinct ARDS subphenotypes
that differ in prognosis, host response, and potentially in response to treatments. ARDS subphenotypes have
not been investigated with regards to nutrition. Thus, Aim 1 will perform biologic assays to facilitate ARDS
subphenotype identification and will test for differences by subphenotype in clinical outcomes, in intestinal
permeability, and in incretin hormones. When released at physiologic levels in response to enteral nutrients,
incretins have beneficial effects on insulin release and glucose metabolism, but when released at
supraphysiologic levels in response to intestinal inflammation, incretins may worsen tolerance to nutrition by
reducing gastric motility. Incretins are not well characterized in ARDS. In Aim 2, this proposal will use
computational approaches that directly model individual treatment effects based on patient covariates allowing
for investigations of treatment response that result from a complex interaction between baseline demographics,
severity of illness, endocrine hormones, and inflammation at an individual patient level. Successful completion
of the proposed Aims will provide new knowledge on biologic responses to nutrition strategies, identify
mechanisms that contribute to heterogeneity of treatment effect at an individual level, and provide direction for
the next generation of precision nutrition studies in ARDS.
项目摘要
营养是急性呼吸窘迫综合征危重患者护理的重要组成部分
(ARDS),他们经常限制自愿摄入,并继发于
他们的病尽管营养不足和不良结果之间存在明显的关联,
特定营养策略的大型多中心试验未能一致地证明临床益处
采用任何特定的方法。具有里程碑意义的NHLBI资助的早期与延迟肠内营养[EDEN]试验
在1000名患者中研究了低水平(营养)与全肠道喂养,
胃肠道并发症,全肠内喂养,没有任何临床益处。随后,目前
指南建议所有ARDS患者低水平喂养,然而,ARDS越来越被认为是一种
异质性疾病和一刀切方法可能并不合适。必不可少的第一步
ARDS患者的个体化营养是确定导致异质性的临床和生物学变量
指个体或群体对治疗的反应不同的治疗效果。因此,这一总体目标
一项建议是通过利用数据和生物标本来描述对营养的不同反应,
伊甸园审判。在目标1中,该建议将调查ARDS亚表型是否在低浓度的
EDEN中的水平与完全肠内营养。最近的研究已经确定了两种不同的ARDS亚型
在预后、宿主反应和对治疗的潜在反应方面不同。ARDS亚型有
在营养方面还没有研究过。因此,目标1将进行生物测定以促进ARDS
亚表型鉴定,并将测试临床结果中亚表型的差异,在肠
渗透性和肠促胰岛素激素。当响应肠内营养素以生理水平释放时,
肠促胰岛素对胰岛素释放和葡萄糖代谢具有有益的作用,但是当在
肠促胰岛素在肠道炎症反应中的超生理水平,可能通过以下方式恶化对营养的耐受性:
降低胃蠕动。肠促胰岛素在ARDS中没有很好的特征。在目标2中,本提案将使用
基于患者协变量直接对个体治疗效果建模的计算方法,
对于由基线人口统计学之间的复杂相互作用引起的治疗反应的研究,
疾病的严重程度、内分泌激素和炎症。成功完成
提出的目标将提供关于营养战略的生物反应的新知识,
在个体水平上导致治疗效果异质性的机制,并为
下一代的ARDS精确营养研究
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Faraaz Ali Shah其他文献
Faraaz Ali Shah的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Faraaz Ali Shah', 18)}}的其他基金
Metabolic Effects of Early Nutritional Support in Sepsis: A Translational Investigation
脓毒症早期营养支持的代谢效应:一项转化研究
- 批准号:
9222927 - 财政年份:2016
- 资助金额:
$ 11.93万 - 项目类别:
Metabolic Effects of Early Nutritional Support in Sepsis: A Translational Investigation
脓毒症早期营养支持的代谢效应:一项转化研究
- 批准号:
9769833 - 财政年份:2016
- 资助金额:
$ 11.93万 - 项目类别:
Effect of Route of Nutritional Support on Metabolic and Inflammatory Outcomes in Sepsis
营养支持途径对脓毒症代谢和炎症结果的影响
- 批准号:
8983231 - 财政年份:2015
- 资助金额:
$ 11.93万 - 项目类别:
Effect of Route of Nutritional Support on Metabolic and Inflammatory Outcomes in Sepsis
营养支持途径对脓毒症代谢和炎症结果的影响
- 批准号:
9150293 - 财政年份:2015
- 资助金额:
$ 11.93万 - 项目类别:
相似海外基金
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 11.93万 - 项目类别:
Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
- 批准号:
10722669 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
- 批准号:
491387 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
- 批准号:
10678788 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
- 批准号:
10646578 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
- 批准号:
23K08447 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
- 批准号:
10601865 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
- 批准号:
23K08360 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
- 批准号:
10722194 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
- 批准号:
10594793 - 财政年份:2023
- 资助金额:
$ 11.93万 - 项目类别:














{{item.name}}会员




